RxDoctor Payments DataLook up a doctor →

Kristi Orbaugh, NP

Nurse Practitioner · Indianapolis, INNPI 1134191679

Payments from drug & device makers

$1,308,090in general payments, 2019–2025

Across 2,434 payments — averaging $537.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$286K
  • AstraZeneca$247K
  • Gilead$145K
  • Daiichi Sankyo Inc.$143K
  • Incyte Corporation$141K
  • Pfizer$61K
  • plus $286K from 18 others

What the payments were for

  • Consulting fees$44,2853%
  • Speaking & faculty fees$853,00265%
  • Travel & lodging$375,14129%
  • Food & beverage$35,4583%
  • Education$2040%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,308,090 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$23,140
Medicare patients
124
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib26$352,988
Abiraterone Acetate12$32,912
OrgovyxRelugolix12$32,823
EliquisApixaban29$31,964
XareltoRivaroxaban19$18,946
Enoxaparin Sodium11$2,786
Letrozole81$2,005
Fentanyl13$1,890
Ondansetron Hcl29$433
Anastrozole29$429
Hydroxyurea13$423
Dexamethasone33$375
Gabapentin14$342
Tamoxifen Citrate13$270
Prochlorperazine Maleate26$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$285,910$352,98826 claims
PfizerEliquis$60,684$31,96429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →